2024年欧洲肿瘤内科学会免疫肿瘤学大会（ESMO IO 2024）即将于12月11日至13日，在瑞士日内瓦隆重举行。本届大会致力于展示肿瘤免疫疗法的最新突破，促进全球学术界的交流与合作，共同推动肿瘤治疗领域的进步。
截至目前，ESMO IO的官方网站已经公布了除LBA（Late-Breaking Abstracts）摘要之外的摘要标题。令人瞩目的是，超过60项中国研究成功入选，彰显了中国在肿瘤学领域的卓越贡献。【肿瘤资讯】特别为您整理了这些入选研究，邀您一同见证中国学者在ESMO IO 2024上的学术魅力和创新成果。
Mini Oral session
摘要号：67MO
标题：Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab in patients with MSS/pMMR locally advanced rectal cancer - A multicentre phase II trial ( mRCAT)
在局部晚期MSS/pMMR直肠癌患者中，采用淋巴结豁免的改良短程放疗联合CAPOX和替雷利珠单抗治疗的多中心II期试验（mRCAT）
讲者：Zhangfa Song，中国杭州
摘要号：171MO
标题：Unraveling iCAF and Tumor Cell Communication: Advancing Novel Adjuvant Immunotherapy Response and Prognostic Prediction via Single-Cell Analysis and Multimodal data-based Models
解析iCAF和肿瘤细胞通讯：通过单细胞分析和多模态数据驱动模型推进新辅助免疫治疗应答和预后预测
讲者：Wei Ren，中国广州
Poster Display session
摘要号：7P
标题：ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
ACOX2干扰MRE11-RAD50-NBS1复合体的稳定性，并在透明细胞肾细胞癌中激活免疫肿瘤微环境
讲者：Shiqi Ye，中国上海
摘要号：21P
标题：Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
TP53突变亚型对NSCLC患者接受抗PD-(L)1免疫治疗疗效的影响
讲者：Lige Wu，中国北京
摘要号：43P
标题：Machine learning radiomics based on CT to predict response to lenvatinib plus Tislelizumab based therapy for unresectable hepatocellular carcinoma
基于CT的机器学习放射组学预测无法切除肝细胞癌患者对仑伐替尼联合替雷利珠单抗治疗的应答
讲者：Gang Chen，中国温州
摘要号：45P
标题：Gut Microbiome Signatures for Exploring the Correlation Between Gut Microbiome and Immune Therapy Response Using Machine Learning Approach
利用机器学习方法探索肠道微生物组与免疫治疗应答相关性的肠道微生物组特征
讲者：Han Li，中国济南
摘要号：46P
标题：Abnormal Gut Microbiota May Cause PD-1 Inhibitor-Related Cardiotoxicity via Suppressing Regulatory T Cells
异常肠道菌群可能通过抑制调节性T细胞导致PD-1抑制剂相关心脏毒性
讲者：Zeeshan Afzal，中国太原
摘要号：51P
标题：Unlocking CAR-T Cell Potential: Lipid Metabolites in Overcoming Exhaustion in Ovarian Cancer
解锁CAR-T细胞潜力：在卵巢癌中克服衰竭的脂质代谢物
讲者：Xiangyu Chang，中国北京
摘要号：62P
标题：Ecto-CRT induction of NKp46 surface expression increases Osimertinib-resistant lung cancer’s sensitivity to NK cells
Ecto-CRT诱导NKp46表面表达增加对奥希替尼耐药肺癌的NK细胞敏感性
讲者：Sumei Chen，中国杭州
摘要号：63P
标题：Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
单细胞RNA测序结合批量RNA测序揭示了胰腺癌组织抑制性巨噬细胞参与肿瘤进展和免疫治疗应答
讲者：BIN Wu，中国嘉兴
摘要号：70P
标题：Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
PD-1阻断联合化疗在恶性NSCLC患者中的疗效
讲者：Haowei Wang，中国上海
摘要号：75P
标题：Real-world Data of Adebrelimab in the First-line Treatment of Patients with Small-cell Lung Cancer
阿得贝利单抗作为SCLC患者一线治疗的真实世界数据
讲者：Yong Song，中国南京
摘要号：82P
标题：Predictive Biomarkers for Neoadjuvant Immunochemotherapy Efficacy in Locally Advanced Cancer Patients: A Retrospective Analysis Based on Changes in Tumor Shrinkage Rate and Lymphocyte Count
局部晚期癌症患者新辅助免疫化疗疗效的预测生物标志物：基于肿瘤退缩率和淋巴细胞计数变化的回顾性分析
讲者：Zhanjie Zhang，中国武汉
摘要号：83P
标题：Effectiveness and Safety of Neoadjuvant Immunochemotherapy with and without Surgery in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study
新辅助免疫化疗在可切除食管鳞状细胞癌患者手术前后的有效性和安全性：一项回顾性队列研究
讲者：Xuqiang Liao，中国海口
摘要号：85P
标题：Impact of Serum Lipid Levels on Immune Therapy-Related Hepatotoxicity in Patients with Pan-cancer: A Cohort Study
血清脂质水平对泛癌患者免疫治疗相关肝毒性的影响：一项队列研究
讲者：Lei Jing，中国上海
摘要号：89P
标题：Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: a systematic review and meta-analysis
在晚期实体瘤中重新使用免疫检查点抑制剂的安全性和有效性：系统综述和荟萃分析
讲者：Hui J. Xu，中国合肥
摘要号：92P
标题：An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
鼻咽癌患者与健康人群治疗前营养和免疫状况差异的研究
讲者：Qiao He，中国成都
摘要号：102P
标题：A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
一线仑伐替尼联合PD-1抑制剂治疗进展后，不可切除肝细胞癌二线治疗有效性的真实世界研究
讲者：Saifeng Li，中国南昌
摘要号：103P
标题：Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma -A multicenter, prospective, single-arm, real-world study
替雷利珠单抗联合放化疗治疗局部晚期食管鳞状细胞癌：一项多中心、前瞻性、单臂、真实世界研究
讲者：Zhihua Wen，中国济南
摘要号：104P
标题：The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
新型PD-1/CTLA-4双特异性抗体卡度尼利单抗（AK104）作为转移性NSCLC二线或更后线治疗的疗效和安全性
讲者：Hualin Chen，中国湛江
摘要号：105P
标题：A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
使用机器学习进行的回顾性研究，分析VEGFR-TKIs和PD-1抑制剂作为MSS mCRC患者的三线或更后线治疗的效果
讲者：Shumei Han，中国济南
摘要号：107P
标题：Efficacy and Safety of First-line TKI Plus ICI Therapy in Metastatic Non-clear Cell Renal Cell Carcinoma: A Real-world Multiple-centre Study
一线TKI联合ICI治疗转移性非透明细胞肾细胞癌的疗效和安全性：一项真实世界多中心研究
讲者：Yulu Peng，中国广州
摘要号：108P
标题：Transarterial Chemoembolization (TACE) Combined With Atezolizumab And Bevacizumab Versus TACE Alone In Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score-Matched Analysis
经动脉化疗栓塞（TACE）联合阿替利珠单抗和贝伐珠单抗与单独TACE在BCLB B期不可切除肝细胞癌患者中的比较：一项回顾性、倾向评分匹配分析
讲者：Hongjie Cai，中国广州
摘要号：109P
标题：Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
一线基于免疫联合系统治疗和脑放疗在治疗驱动基因阴性NSCLC BM患者中的有效性
讲者：Mengxing You，中国北京
摘要号：110P
标题：Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: a prospective, real-world study
阿得贝利单抗作为ES-SCLC一线治疗的安全性和有效性：一项前瞻性、真实世界研究
讲者：Junxu Wen，中国济南
摘要号：111P
标题：Real-world treatment patterns and clinical outcomes in Chinese stage III Non-small Cell Lung Cancer (NSCLC) patients: results of MOOREA study
中国III期NSCLC患者的真实治疗模式和临床结果：MOOREA研究的结果
讲者：Ligang Xing，中国济南
摘要号：112P
标题：Serplulimab Combined with Chemotherapy and Anlotinib for Extensive-stage Small-cell Lung Cancer: a Multicenter Real-world Experience
斯鲁利单抗联合化疗和安罗替尼治疗ES-SCLC：一项多中心真实世界经验
讲者：Jun Wang，中国石家庄
摘要号：114P
标题：Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS≤5：Updated results from a real-world study
卡度尼利单抗联合化疗作为转移性胃或胃食管结合部腺癌PD-L1 CPS≤5患者一线（1L）治疗：一项真实世界研究的更新结果
讲者：Qi Xu，中国杭州
摘要号：116TiP
标题：An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
一项伞形试验（RECHALLENGE），旨在评估在临床试验中疾病进展后，晚期实体瘤患者接受联合或序贯免疫治疗的安全性和初步疗效
讲者：Hui-lei Miao，中国北京
摘要号：125P
标题：Enhancing the Efficacy of Neoantigen Tumor Vaccines in Melanoma Treatment through Different Administration Times
通过不同给药时间提高黑色素瘤治疗中新抗原肿瘤疫苗的疗效
讲者：Kai Xiao，中国成都
摘要号：130P
标题：Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: preliminary results from a phase II trial
双特异性抗体卡度尼利单抗在dMMR/MSI-H局部晚期结直肠癌中的新辅助治疗：II期试验的初步结果
讲者：Caifeng Gong，中国北京
摘要号：131P
标题：The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
卡度尼利单抗联合或不联合曲妥珠单抗与SOX方案作为晚期胃或胃食管结合部腺癌一线（1L）治疗的疗效和安全性
讲者：Wenhui Yang，中国太原
摘要号：132P
标题：An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
一项开放标签、前瞻性II期研究：卡度尼利单抗联合新辅助化疗治疗晚期卵巢癌患者（AK104-IIT-003）
讲者：Jie Tang，中国长沙
摘要号：133P
标题：The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: a single-arm, open-label, multicenter phase 2 clinical trial
KN046联合阿昔替尼治疗既往未经治疗及免疫检查点抑制剂治疗的晚期NSCLC的疗效和安全性：一项单臂、开放标签、多中心II期临床试验
讲者：Li Zhang，中国广州
摘要号：134P
标题：Intracranial (IC) Progression-Free Survival (PFS) with Ivonescimab (Ivo) Compared to Placebo in the HARMONi-A Trial of Patients (Pts) with Previously Treated EGFR Mutation-Positive (EGFRm+) Non-Small Cell Lung Cancer (NSCLC)
在既往接受过治疗的EGFRm+ NSCLC患者的HARMONi-A试验中，依沃西单抗与安慰剂相比的颅内PFS
讲者：Li Zhang，中国广州
摘要号：135P
标题：Efficacy and safety of Tislelizumab combined with Bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): a prospective, single-arm Phase II clinical study
替雷利珠单抗联合支气管动脉灌注（BAI）化疗在潜在可切除IIIB期NSCLC中的疗效和安全性：一项前瞻性、单臂II期临床研究
讲者：Xu Ma，中国上海
摘要号：136P
标题：Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: an updated analysis
替雷利珠单抗联合化疗及/或贝伐珠单抗治疗EGFR突变非鳞状NSCLC患者在EGFR TKI治疗进展后的疗效和安全性：一项更新分析
讲者：Baohui Han，中国上海
摘要号：137P
标题：Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Tislelizumab for Unresectable Hepatocellular Carcinoma: A Single-arm, Phase II Study
肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗治疗不可切除肝细胞癌：一项单臂、II期研究
讲者：Jianbing Wu，中国南昌
摘要号：138P
标题：Interim results of Neoadjuvant TACE Plus Lenvatinib and Tislelizumab in Resectable HCC at CNLC Stages IB and IIA with High-risk of recurrence: A Prospective, Single-Arm, Phase II Trial
新辅助TACE联合仑伐替尼和替雷利珠单抗在可切除HCC中的CNLC IB期和IIA期高复发风险患者的中期结果：一项前瞻性、单臂、II期试验
讲者：Yuhua Zhang，中国杭州
摘要号：139P
标题：Ablation combined with tislelizumab in treating hepatocellular carcinoma: a phase II trial
消融联合替雷利珠单抗治疗肝细胞癌：一项II期试验
讲者：Yangxun Pan，中国广州
摘要号：140P
标题：Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective ,single-arm, phase 2 study
替雷利珠单抗联合仑伐替尼和经动脉化疗栓塞（TACE）新辅助治疗可切除CNLC IIa-IIb期肝细胞癌：一项前瞻性、单臂、2期研究
讲者：Zhibo Zhang，中国福州
摘要号：141P
标题：Efficacy and safety of Tislelizumab(T) combined with Gemcitabine and Cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: a prospective, phase II study
替雷利珠单抗联合吉西他滨和顺铂用于根治性局部手术后局部肌浸润性膀胱癌（MIBC）患者的疗效和安全性：一项前瞻性、II期研究
讲者：Ming Cao，中国上海
摘要号：145P
标题：Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
基于派安普利单抗的联合新辅助/辅助治疗用于可切除的局部晚期NSCLC患者：一项II期、前瞻性研究（ALTER-L043）的更新
讲者：Changli Wang，中国天津
摘要号：146P
标题：Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: a single-arm, single-center, phase II clinical trial
新辅助阿得贝利单抗联合化疗治疗食管胃结合部腺癌：一项单臂、单中心、II期临床试验
讲者：Jinqiang Liu，中国西安
摘要号：147P
标题：Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial
斯鲁利单抗联合化疗在可切除食管鳞状细胞癌新辅助治疗中的研究：一项单臂II期试验
讲者：Zixiang Wu，中国杭州
摘要号：148P
标题：Neoadjuvant Camrelizumab plus Metronomic Chemotherapy in Patients with advanced esophageal squamous cell carcinomas：a randomized phase 2 trial
新辅助卡瑞利珠单抗联合代谢化疗治疗晚期食管鳞状细胞癌患者的随机II期试验
讲者：JIE LIU，中国上海
摘要号：149P
标题：Toripalimab and Chemotherapy as First Line Combination in Advanced Thymic Carcinoma: A Prospective, Single-Arm, Phase II Trial
特瑞普利单抗联合化疗作为晚期胸腺癌一线治疗方案：一项前瞻性、单臂、II期试验
讲者：Kai Zhu，中国北京
摘要号：153P
标题：Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): preliminary results from a phase 2 study
Tim-3阻断剂TQB2618与PD-1阻断剂联合用于免疫治疗抵抗性复发/转移性鼻咽癌（R/M NPC）患者的初步结果：一项II期研究
讲者：Cheng Xu，中国广州
摘要号：180P
标题：Chronic circadian disruption promotes melanoma progression by interfering with NK cells
慢性昼夜节律紊乱通过干扰NK细胞促进黑色素瘤进展
讲者：Shuwen Xiao，中国成都
摘要号：186P
标题：Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
通过功能基因组学和临床来源的活检揭示并克服PD(L)1抗体耐药性
讲者：BIN XIE，中国上海
摘要号：187P
标题：Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
单细胞RNA测序阐明了上皮细胞、免疫细胞和成纤维细胞在高级别浆液性卵巢癌中的相互作用
讲者：Xiaoting Zhao，中国北京
摘要号：188P
标题：Single-cell and Spatial Transcriptomics Delineate the Microstructure and Immune Landscape of Intrahepatic Cholangiocarcinoma in the Leading-edge Area
单细胞和空间转录组学描绘了肝内胆管癌在前沿区域的微结构和免疫微环境
讲者：Zuyin Li，中国北京
摘要号：189P
标题：“Image-guided Labeling of Live Cells in TLS for Single Cell Transcriptomics
TLS中单细胞转录组学的图像引导活细胞标记
讲者：Mengrui Cao，中国北京
摘要号：199P
标题：Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors
肿瘤中性粒细胞百科全书：深入探索抗原呈递的战士
讲者：Yingcheng Wu，中国上海
摘要号：200P
标题：CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
CXCR1+中性粒细胞浸润调控第三代EGFR-TKI在EGFR突变NSCLC中的应答
讲者：Haowei Wang，中国上海
摘要号：203P
标题：Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
靶向IL-33重塑肿瘤微环境并增强对抗PD-L1免疫治疗的抗肿瘤应答
讲者：Xuyao Zhang，中国上海
摘要号：207P
标题：ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
ZEB2抑制缓解了EGFR-TKI耐药NSCLC中TAMs介导的免疫抑制
讲者：Yunhuan Liu，中国上海
摘要号：211P
标题：Single-cell Characterization of Differentiation Trajectories and Drug Resistance Features in Gastric Cancer with Peritoneal Metastasis
单细胞特征化分析胃癌伴腹膜转移的分化轨迹和耐药特征
讲者：Haoxin Peng，中国北京
摘要号：212P
标题：YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
YAP/TEAD4/SP1诱导的VISTA表达作为结直肠癌中肿瘤细胞内在的免疫抑制机制
讲者：Zhehui Zhu，中国上海
摘要号：217P
标题：Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
肿瘤源性CCL15调节癌症相关成纤维细胞中的RNA m6A甲基化以促进肝细胞癌生长
讲者：Yueguo Li，中国天津
摘要号：220P
标题：Correlation research between oral flora diversity radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
口腔鳞状细胞癌术后放射性口腔炎与口腔微生物多样性的相关性研究
讲者：Qin Zheng，中国南京
如有遗漏或错误，欢迎广大读者提醒及指正。
排版编辑：肿瘤资讯-Bear
苏公网安备32059002004080号
